TAK vs NBIX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NBIX Captures Institutional Edge (3โ1 Pillars ยท 5โ5 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Neurocrine Biosciences Inc (NBIX) driven by superior Valuation, Growth & Margin, Options & Structure while TAK counters with relative strength in Momentum & Technical. Fundamentally, TAK trades at 12.7x Forward P/E with 16.6% operating margin (+6.7% YoY revenue) versus NBIX at 13.6x Forward P/E and 26.6% operating margin (+41.2% YoY). In options structure, TAK sits in UNCLASSIFIED (5th %ile IV; Dealer Gamma Walls on Pro) against NBIX sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | TAK | NBIX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $67.5B | $17.1B | Larger Scale | TAK |
| Trailing P/E Ratio Valuation | N/M | 25.1x | Lower Multiple | NBIX |
| Forward P/E Ratio Valuation | 12.7x | 13.6x | Lower Multiple | TAK |
| Revenue Growth (YoY) Growth | +6.7% | +41.2% | Higher Growth | NBIX |
| Operating Margin (TTM) Profitability | 16.6% | 26.6% | Higher Margin | NBIX |
| Net Profit Margin Profitability | 0.9% | 19.0% | Higher Margin | NBIX |
| Return on Equity (ROE) Capital Efficiency | 0.6% | 20.4% | Higher ROE | NBIX |
| 52-Week Range Position Momentum | 97% ($14โ$22) | 68% ($122โ$186) | Stronger Trend | TAK |
| Beta / 30D Volatility Risk Regime | -0.02ฮฒ ยท 22% Vol | 0.60ฮฒ ยท 54% Vol | Lower Realized Risk | TAK |
| Unified Institutional Score Composite Signal | 47.7 / 100 (HOLD) | 31.4 / 100 (SELL) | Higher Composite | TAK |